Human mu‐opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin‐induced painful neuropathy
Authors:
Open Access
Abstract
BACKGROUND: The A118G polymorphism of the mu‐opioid receptor gene (OPRM1), resulting in the substitution of an amino acid, has been found to be associated with functional effects and response to opioid treatment. The purpose of this study was to assess whether this polymorphism contributes to the variability in response to tramadol/acetaminophen combination tablets (Ultracet) for treating oxaliplatin‐induced painful neuropathy.METHODS: A total of 96 patients with adenocarcinoma of the colon or rectum (n = 84), or stomach (n = 12) who had developed oxaliplatin‐induced painful neuropathy were enrolled. Ultracet was administered at 1 tablet every 6 hours, and pain was assessed and scored using a visual analog scale (VAS). The OPRM1 A118G polymorphism was examined with a polymerase chain reaction‐direct sequencing method.RESULTS: The allelic frequency of variant (118G) allele was 39.6%, and the prevalence of OPRM1‐118 AA, AG, and GG genotypes was 31.3% (n = 30), 58.3% (n = 56), and 10.4% (n = 10), respectively. For all patients, the mean pre‐treatment and post‐treatment VAS scores were 3.1 and 2.1, respectively (P < .001). Patients with AA genotype had a better analgesic effect than those with G allele variants (AG or GG genotypes). Pre‐treatment and post‐treatment VAS scores for patients with G allele variants were 3.1 and 2.6, respectively; however, for patients with AA genotype, pre‐treatment and post‐treatment VAS scores were 3.0 and 0.9, respectively (P < .001). The requirement for rescue analgesia was also higher for patients with G allele variants (P = .01).CONCLUSIONS: These data suggest that Ultracet is effective in the management of oxaliplatin‐induced painful neuropathy. A118G polymorphism of OPRM1, by altered function of the mu‐opioid receptor and consequential analgesic effect on opioid agents, could be a key determinant for decreased response to Ultracet. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 42 references indexed in Scilit:
- Methadone initiation and rotation in the outpatient setting for patients with cancer painCancer, 2009
- Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the RatThe Journal of Pain, 2009
- Association of morphine-induced antinociception with variations in the 5′ flanking and 3′ untranslated regions of the μ opioid receptor gene in 10 inbred mouse strainsPharmacogenetics and Genomics, 2008
- Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic SymptomsJournal of Pain and Symptom Management, 2008
- Pain in oxaliplatin-induced neuropathy – Sensitisation in the peripheral and central nociceptive systemEuropean Journal of Cancer, 2007
- Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II studyInvestigational New Drugs, 2006
- Human Opioid Receptor A118G Polymorphism Affects Intravenous Patient-controlled Analgesia Morphine Consumption after Total Abdominal HysterectomyAnesthesiology, 2006
- Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium InfusionsClinical Cancer Research, 2004
- TramadolDrugs, 2000
- Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologramLife Sciences, 1995